This delay in PD onset represents around 30% of a typical Parkinsons patients life expectancy, which may contribute to lower prevalence of diabetes in the PD population, as some diabetic patients may not live long enough to develop PD
Why it matters: As GLP-1 demand grows, telehealth companies in the weight loss drug space must choose between tie-ups with riskier compounding pharmacies or more stable deals with GLP-1 drugmakers Novo and Eli Lilly
As a GHRH secretagogue that is subcutaneously injected, ipamorelin likely causes side effects related to frequent injections such as pain, rash or soreness at injection sites, in common with other forms of GH therapies [19]
3 An analysis of kidney outcomes found a 22% lower risk of serious kidney problems, including kidney failure and sustained eGFR decline
Feb 13 2020;43(2)doi:10.1093/sleep/zsz254
As far as NASH is concerned, liraglutide has been most studied, demonstrating significant improvement of steatohepatitis (histological resolution of NASH in 39% of the patients in the treatment group vs